Multimodal Neuroimaging of Treatment Effects in Adolescent Mania

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

169 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Specific Aim 1: To determine the effects of treatment with quetiapine or lithium on brain activation in adolescents. The investigators will use functional magnetic resonance imaging (fMRI) to examine brain activation during an attentional task.

Specific Aim 2: To determine the effects of treatment with quetiapine or lithium on neurometabolite measures, early in their illness course. The investigators will use 1H-MRS to identify myo-inositol (mI), N-acetyl aspartate (NAA), and glutamate (Glu) levels in prefrontal ALN regions.

Specific Aim 3: To determine the relationships among the changes in brain activation and neurometabolite measures, as well as symptomatic improvement in manic adolescents.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Functional and Neurochemical Brain Changes in First-episode Bipolar Mania

NCT00609193

Bipolar Disorder

COMPLETED

Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR

NCT00879307

BIPOLAR DISORDER

UNKNOWN PHASE3

Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder

NCT03336918

Bipolar Disorder Bipolar I Depression Bipolar II Depression +3 more

ACTIVE_NOT_RECRUITING

Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania

NCT00879632

BIPOLAR DISORDER

UNKNOWN

Functional and Neurochemical Brain Changes Bipolar Depression

NCT00608296

Depression, Bipolar

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypotheses 1 \& 2 predict that following 6 weeks of treatment with lithium or quetiapine, manic adolescents who demonstrate symptomatic improvement will exhibit normalized (decreased) VLPFC and ACC activation and increased activation of compensatory posterior attentional brain areas as well as normalization of VLPFC and ACC neurometabolite measures (increased NAA and decreased Glu levels) compared with those who do not experience symptomatic improvement and healthy adolescents.

Hypothesis 3 predicts significant associations between fMRI activation changes (i.e. decreased activation in VLPFC and ACC ROIs and increased activation in the posterior attention ROI) and MRS changes (increases in NAA and decreases in Glu levels in the VLPFC and ACC) for patients who exhibit symptomatic improvement with either treatment.

Hypothesis 4 predicts that decreases in mI levels at 1 week will be associated with lithium, but not quetiapine, response at endpoint.

In contrast, Hypothesis 5 predicts higher baseline Cho levels will be associated with quetiapine, but not lithium, response at endpoint.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mania Bipolar Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1--Quetiapine & Placebo

Quetiapine \& Placebo in the place of Lithium

Group Type ACTIVE_COMPARATOR

Quetiapine & Placebo

Intervention Type DRUG

Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.

2-- Lithium & Placebo

Lithium \& Placebo in the place of Quetiapine

Group Type ACTIVE_COMPARATOR

Lithium and Placebo

Intervention Type DRUG

Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.

Placebo

Sugar Pill (Placebo) given to mimic drug

Group Type PLACEBO_COMPARATOR

Healthy Controls

Intervention Type OTHER

Healthy control (patients given placebo -- sugar pill intended to mimic drug)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quetiapine & Placebo

Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.

Intervention Type DRUG

Lithium and Placebo

Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.

Intervention Type DRUG

Healthy Controls

Healthy control (patients given placebo -- sugar pill intended to mimic drug)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

Inclusion - Bipolar Disorder Subjects:

* DSM-IV-TR12 criteria for bipolar disorder, type I, manic or mixed episode, diagnosed by the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS)166,101,102-103,104-105,108
* Baseline YMRS112-114 score \> 20;
* Ages 12-17 years 11 months old;
* Fluent in English;
* Provision of written informed consent by a legal guardian and written assent by the subject;
* Tanner scale stages III-V167, in order to include only post-pubescent subjects and minimize brain changes associated with the onset of puberty;168-169
* Less than 2 years from onset of bipolar disorder, defined by age at onset of first DSM-IV-TR affective episode (mania, hypomania, depression or mixed), to establish that our sample is early in their illness course;
* No prior psychiatric hospitalizations, \<3 months of lifetime psychotropic medication exposure (with the exception of psychostimulants, since excluding patients with psychostimulant exposure would significantly limit the generalizability of our findings), and no active psychotropic medication during the week (72 hours for psychostimulants and benzodiazepines) prior to the index assessment (no treatment with fluoxetine during the prior month). Please note that patients will NOT be taken off medications for the purpose of this study; instead, this criterion is to exclude subjects receiving treatment at the time of index assessment;
* Does not have a history of intolerance or non-response to lithium or quetiapine;
* Manic or depressive symptoms do not result entirely from acute medical illness or acute intoxication or withdrawal from drugs or alcohol as determined by medical evaluation and rapid symptom resolution;
* No lifetime DSM-IV-TR diagnosis of post-traumatic stress disorder (PTSD), since PTSD has been associated with abnormalities in prefrontal NAA and function170-171,172. Furthermore, bipolar patients with co-occurring PTSD are less likely to respond to lithium monotherapy, and often need a serotonin specific reuptake inhibitor (SSRI) as adjunctive treatment to a mood stabilizer.173,174 ;
* If female and of child bearing potential, agrees to use one of the following method of birth control: complete abstinence from sexual intercourse, barrier (diaphragm or condom), or oral/injectable contraceptive.

Inclusion - Healthy Controls:

* Ages of 12-17 years and 11 month;
* No history of any DSM-IV-TR Axis I disorder (nicotine dependence is permitted);
* No first- or second-degree relatives with an affective or psychotic disorder;
* No medications with central nervous system effects within 5 half-lives;
* Fluent in English;
* Tanner stage III-V;
* Provision of informed consent and assent.

Exclusion - Bipolar Subjects \& Healthy Controls:

* Contraindication to an MRI scan (e.g., braces or claustrophobia);
* An unstable medical or neurological illness that could influence fMRI or MRS results;
* IQ \< 70, as determined by The Wechsler Abbreviated Scale of Intelligence (WASI) ;
* A positive pregnancy test;
* A history of major medical or neurological illness or a significant episode (\> 10 minutes) of loss of consciousness;
* Any lifetime DSM-IV-TR substance use disorder (nicotine dependence is permitted);
* A lifetime DSM-IV-TR diagnosis of any pervasive developmental disorder;
* The patient lives \>100 miles from the University of Cincinnati or is not able to attend follow-up visits.

Minimum Eligible Age

12 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes